VivoSeq
Oncology

Human Papillomavirus-Related Carcinoma

1

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Human Papillomavirus-Related Carcinoma is an early-stage landscape with 1 program across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

HPV16 RG1 VLP Vaccine

National Cancer Institute (NCI)

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Prospective, Single-arm, Open-label, Non-randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-booster Dosing Schedule Among 9-11 Year-old Girls and Boys
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02568566·201 enrolled
A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, A Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05985681·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)